{"id":231,"date":"2025-05-08T14:54:01","date_gmt":"2025-05-08T14:54:01","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=231"},"modified":"2026-09-07T18:55:55","modified_gmt":"2026-09-07T18:55:55","slug":"igf-1-lr3-vs-des-structural-differences-research","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/igf-1-lr3-vs-des-structural-differences-research\/","title":{"rendered":"IGF-1 LR3 vs IGF-1 DES: Structural Differences in Research"},"content":{"rendered":"\n<div class=\"ez-toc-v2_0_81 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\" id=\"ez-toc-container\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<p><span class=\"ez-toc-title-toggle\"><a aria-label=\"Toggle Table of Content\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" href=\"#\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg class=\"list-377408\" fill=\"none\" height=\"20px\" style=\"fill: #999;color:#999\" viewbox=\"0 0 24 24\" width=\"20px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg baseprofile=\"tiny\" class=\"arrow-unsorted-368013\" height=\"10px\" style=\"fill: #999;color:#999\" version=\"1.2\" viewbox=\"0 0 24 24\" width=\"10px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"><\/path><\/svg><\/span><\/span><\/span><\/a><\/span><\/p><\/div>\n<nav>\n<ul class=\"ez-toc-list ez-toc-list-level-1\">\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/igf-1-lr3-vs-des-differences-purchase-guide\/#INTRODUCTION_TO_INSULIN-LIKE_GROWTH_FACTOR_IGF-1\">INTRODUCTION TO INSULIN-LIKE GROWTH FACTOR (IGF-1)<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/igf-1-lr3-vs-des-differences-purchase-guide\/#VARIANTS_OF_IGF-1_IGF-1_LR3_AND_IGF_DES_13\">VARIANTS OF IGF-1: IGF-1 LR3 AND IGF DES 1,3<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/igf-1-lr3-vs-des-differences-purchase-guide\/#IGF-1_LR3_VS_IGF_DES_13_REVIEW\">IGF-1 LR3 VS IGF DES 1,3 REVIEW<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/igf-1-lr3-vs-des-differences-purchase-guide\/#WHAT_IS_INSULIN_LIKE_GROWTH_FACTOR_IGF-1_LR3_VS_IGF_DES_13\">WHAT IS INSULIN LIKE GROWTH FACTOR IGF-1 LR3 VS IGF DES 1,3?<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/igf-1-lr3-vs-des-differences-purchase-guide\/#IGF-1_LR3_VS_IGF_DES_13_MOA_MECHANISM_OF_ACTION_AND_HALF_LIFE\">IGF-1 LR3 VS IGF DES 1,3 MOA (MECHANISM OF ACTION) AND HALF LIFE<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/igf-1-lr3-vs-des-differences-purchase-guide\/#IGF-1_LR3_AND_IGF_DES_13_EFFECTS\">IGF-1 LR3 AND IGF DES 1,3 EFFECTS<\/a><\/li>\n\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/igf-1-lr3-vs-des-differences-purchase-guide\/#IGF_DES_13_VS_IGF-1_LR3_RESULTS\">IGF DES 1,3 VS IGF-1 LR3 RESULTS<\/a><\/li>\n\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lotilabs.com\/resources\/igf-1-lr3-vs-des-differences-purchase-guide\/#WHERE_TO_BUY_IGF_DES_13_and_IGF-1_LR3\">WHERE TO BUY IGF DES 1,3 and IGF-1 LR3<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lotilabs.com\/resources\/igf-1-lr3-vs-des-differences-purchase-guide\/#References\">References<\/a><\/li>\n<\/ul>\n<\/nav>\n<\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"INTRODUCTION_TO_INSULIN-LIKE_GROWTH_FACTOR_IGF-1\"><\/span><span class=\"ez-toc-section\" id=\"INTRODUCTION_TO_INSULIN-LIKE_GROWTH_FACTOR_IGF-1\"><\/span><span class=\"ez-toc-section\" id=\"INTRODUCTION_TO_INSULIN-LIKE_GROWTH_FACTOR_IGF-1\"><\/span>INTRODUCTION TO <a href=\"https:\/\/lotilabs.com\/buy\/igf-1-lr3\/\" rel=\"noopener noreferrer\" target=\"_self\">INSULIN-LIKE GROWTH FACTOR (IGF-1)<\/a><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"VARIANTS_OF_IGF-1_IGF-1_LR3_AND_IGF_DES_13\"><\/span><span class=\"ez-toc-section\" id=\"VARIANTS_OF_IGF-1_IGF-1_LR3_AND_IGF_DES_13\"><\/span><span class=\"ez-toc-section\" id=\"VARIANTS_OF_IGF-1_IGF-1_LR3_AND_IGF_DES_13\"><\/span>VARIANTS OF IGF-1: <a href=\"https:\/\/lotilabs.com\/buy\/igf-1-lr3\/\" rel=\"noopener noreferrer\" target=\"_self\">IGF-1 LR3<\/a> AND IGF DES 1,3<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>IGF-1 exists in two main variants: IGF-1 LR3 and IGF DES 1,3. IGF-1 LR3 is a modified IGF-1 with an extended amino acid sequence that has 13 additional amino acids at the N-terminus and a substitution of arginine for glutamic acid at position 3. IGF DES 1,3 is a truncated IGF-1 that is missing the first 3 amino acids at the N-terminus.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IGF-1_LR3_VS_IGF_DES_13_REVIEW\"><\/span><span class=\"ez-toc-section\" id=\"IGF-1_LR3_VS_IGF_DES_13_REVIEW\"><\/span><span class=\"ez-toc-section\" id=\"IGF-1_LR3_VS_IGF_DES_13_REVIEW\"><\/span>IGF-1 LR3 VS IGF DES 1,3 REVIEW<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Although functionally related, <strong>IGF-1 LR3<\/strong> and IGF DES 1,3 are two different compounds with different structures and degree of actions. This article will try to explore the thin line that separates these closely related compounds so we can identify them uniquely for further research.<\/p>\n<p>Additional information will be posted on where to buy them for any biological engineering or research purpose.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Differences_Between_IGF-1_LR3_and_IGF-1_DES\"><\/span><span class=\"ez-toc-section\" id=\"Key_Differences_Between_IGF-1_LR3_and_IGF-1_DES\"><\/span><span class=\"ez-toc-section\" id=\"Key_Differences_Between_IGF-1_LR3_and_IGF-1_DES\"><\/span>Key Differences Between IGF-1 LR3 and IGF-1 DES<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>IGF-1 LR3 stands for Insulin-like Growth Factor-1, Long Arginine 3. The compound is a non-natural or artificial protein. It is a longer version of Insulin-like Growth Factor-1 (IGF-1). Structurally IGF-1 LR3 is different from its patent compound because of the presence of Arginine instead of glutamic acid at the 3rd position of its amino acid sequence and 13 extra amino acids at the N-terminus. This makes it loosely bound to Insulin-like Growth Factor Binding Proteins (IGFBPs). IGF-1 LR3 and IGF DES 1,3 are two groups of IGF-1 variants, each with distinct structural and functional properties.<\/p>\n<p>The significance of this weak binding to IGFBPs is that the compound can exert more pharmacological action in animal subjects since IGFBPs decrease the pharmacological activity of hormones that are strongly bound to it. IGF-1 LR3 has a longer half-life compared to the base form of IGF-1, allowing for a longer duration of activity in the body.<\/p>\n<p>IGF DES 1,3 stands for Insulin-like Growth Factor Desamino 1,3. It is a natural variant of IGF-1 and extracted from human brain, porcine uterus and bovine colostrum. The compound lacks the first 3 amino acids at the N-terminus which are present in the parent compound.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IGF-1_LR3_VS_IGF_DES_13_MOA_MECHANISM_OF_ACTION_AND_HALF_LIFE\"><\/span><span class=\"ez-toc-section\" id=\"IGF-1_LR3_VS_IGF_DES_13_MOA_MECHANISM_OF_ACTION_AND_HALF_LIFE\"><\/span><span class=\"ez-toc-section\" id=\"IGF-1_LR3_VS_IGF_DES_13_MOA_MECHANISM_OF_ACTION_AND_HALF_LIFE\"><\/span>IGF-1 LR3 VS IGF DES 1,3 MOA (MECHANISM OF ACTION) AND HALF LIFE<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 class=\"wp-block-heading\"><strong>IGF-1 LR3 Mechanism of Action &amp; Half-Life<\/strong><\/h3>\n<p>To get even better results than their parent IGF-1, IGF DES 1,3 and IGF-1 LR3 were used separately on animal subjects for trials. It was observed that they bind to Insulin-like Growth Factor Binding Protein (IGFBP) in varying degree. IGF-1 LR3 stays in the host\u2019s body for 20-30 hours. That\u2019s a long half-life, it can exert its pharmacological actions in the host\u2019s body for the same duration.<\/p>\n\n<p>IGF Des 1, 3 on the other hand binds to receptors of cells that are already deteriorated due to production of lactic acid during exercise. That means they can be used and can quickly bind to these receptors of worn-out cells and trigger cellular division and hyperplasia during exercise.<\/p>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IGF-1_LR3_AND_IGF_DES_13_EFFECTS\"><\/span><span class=\"ez-toc-section\" id=\"IGF-1_LR3_AND_IGF_DES_13_EFFECTS\"><\/span><span class=\"ez-toc-section\" id=\"IGF-1_LR3_AND_IGF_DES_13_EFFECTS\"><\/span>IGF-1 LR3 AND IGF DES 1,3 EFFECTS<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 class=\"wp-block-heading\"><strong>Effects of IGF-1 LR3<\/strong><\/h3>\n<p>The effects of IGF-1 LR3 and IGF DES 1,3 are different due to their structural variations and half-lives.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>IGF-1 DES Mechanism of Action &amp; Half-Life<\/strong><\/h3>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IGF-1_LR3_vs_IGF-1_DES_Key_Differences_at_a_Glance\"><\/span><span class=\"ez-toc-section\" id=\"IGF-1_LR3_vs_IGF-1_DES_Key_Differences_at_a_Glance\"><\/span><strong>IGF-1 LR3 vs IGF-1 DES: Key Differences at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The following table summarizes the primary structural, pharmacokinetic, and research application differences between IGF-1 LR3 and IGF-1 DES:<\/p>\n<table style=\"width:100%;border-collapse:collapse;\">\n<thead>\n<tr style=\"background-color:#f1f0f0;\">\n<th style=\"border:1px solid #ccc;padding:8px;text-align:left;\">Property<\/th>\n<th style=\"border:1px solid #ccc;padding:8px;text-align:left;\">IGF-1 LR3<\/th>\n<th style=\"border:1px solid #ccc;padding:8px;text-align:left;\">IGF-1 DES<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #ccc;padding:8px;\"><strong>Structure<\/strong><\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\">+13 amino acids at N-terminus; Arg substitution at position 3<\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\">Missing first 3 N-terminal amino acids (Gly-Pro-Glu deletion)<\/td>\n<\/tr>\n<tr style=\"background-color:#f9f9f9;\">\n<td style=\"border:1px solid #ccc;padding:8px;\"><strong>Half-Life<\/strong><\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\">20\u201330 hours (systemic, extended)<\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\">20\u201330 minutes (localized, rapid)<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ccc;padding:8px;\"><strong>IGFBP Binding<\/strong><\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\">Reduced \u2014 circulates freely longer<\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\">Significantly reduced \u2014 high local bioavailability<\/td>\n<\/tr>\n<tr style=\"background-color:#f9f9f9;\">\n<td style=\"border:1px solid #ccc;padding:8px;\"><strong>Receptor Affinity<\/strong><\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\">Standard IGF-1 receptor binding<\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\"><\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ccc;padding:8px;\"><strong>Primary Research Use<\/strong><\/td>\n\n<\/tr>\n<tr style=\"background-color:#f9f9f9;\">\n<td style=\"border:1px solid #ccc;padding:8px;\"><strong>Signaling Pathway<\/strong><\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\">PI3K\/Akt\/mTOR; sustained systemic activation<\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\">PI3K\/Akt\/mTOR + MAPK; rapid localized activation<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ccc;padding:8px;\"><strong>Administration (Research)<\/strong><\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\"><\/td>\n<td style=\"border:1px solid #ccc;padding:8px;\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>All compounds are for in-vitro and preclinical laboratory research use only (RUO). Not for human or veterinary use.<\/em><\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IGF_DES_13_VS_IGF-1_LR3_RESULTS\"><\/span><span class=\"ez-toc-section\" id=\"IGF_DES_13_VS_IGF-1_LR3_RESULTS\"><\/span><span class=\"ez-toc-section\" id=\"IGF_DES_13_VS_IGF-1_LR3_RESULTS\"><\/span>IGF DES 1,3 VS IGF-1 LR3 RESULTS<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 class=\"wp-block-heading\"><strong>IGF-1 LR3 Research Results<\/strong><\/h3>\n\n<p>Specific muscles of the rats were dosed with a measured vial of the compound.<\/p>\n<h3 class=\"wp-block-heading\"><strong>Effects of IGF-1 DES<\/strong><\/h3>\n<p>IGF-1 Des 1,3 was administered locally to a part of the body for development of only that part, IGF-1 LR3 was administered to a part of an animal subject for overall body effect or development. Also IGF-1 LR3 lasts more than 20 hours in the host\u2019s body while IGF Des 1,3 has 30 minutes half life.<\/p>\n<p>Low blood sugar was recorded after serial administrations of IGF Des 1,3 to animal subjects. Both compounds also enhanced proliferation of cancerous cells in rats with cancerous tumours. IGF Des 1,3 caused reversed testicular atrophy in male Rats with withered testicles.<\/p>\n\n<p>IGF-1 is also linked to atherosclerosis and vascular aging, studies have shown its role in modulating glutathione peroxidase expression and activity in vascular endothelial cells. But misuse of IGF-1 in sports is a big concern and we need to develop effective detection methods to prevent abuse and ensure fair competition.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"WHERE_TO_BUY_IGF_DES_13_and_IGF-1_LR3\"><\/span><span class=\"ez-toc-section\" id=\"WHERE_TO_BUY_IGF_DES_13_and_IGF-1_LR3\"><\/span><span class=\"ez-toc-section\" id=\"WHERE_TO_BUY_IGF_DES_13_and_IGF-1_LR3\"><\/span>WHERE TO BUY IGF DES 1,3 and IGF-1 LR3<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>IGF-1 LR3 and IGF DES 1,3 are available at Loti Labs for in-vitro and preclinical research use. <a href=\"https:\/\/lotilabs.com\/buy\/igf-1-lr3\/\" rel=\"noopener noreferrer\" target=\"_self\">Purchase IGF-1 LR3 from Loti Labs<\/a> \u2014 supplied in 1mg vials, \u226598% purity verified by HPLC.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol class=\"wp-block-list\">\n<li>Philippou, A., Maridaki, M., Halapas, A., &amp; Koutsilieris, M. (2014). <em>Journal of Muscle Research and Cell Motility<\/em>, 35(1), 1-10. <a href=\"https:\/\/doi.org\/10.1007\/s10974-013-9371-8\" rel=\"noopener noreferrer\" target=\"_self\">https:\/\/doi.org\/10.1007\/s10974-013-9371-8<\/a><\/li>\n<li>Le Roith, D., Bondy, C., Yakar, S., Liu, J.-L., &amp; Butler, A. A. (2001). The somatomedin hypothesis: 2001. <em>Endocrine Reviews<\/em>, 22(1), 53-74. <a href=\"https:\/\/doi.org\/10.1210\/edrv.22.1.0428\" rel=\"noopener noreferrer\" target=\"_self\">https:\/\/doi.org\/10.1210\/edrv.22.1.0428<\/a><\/li>\n<li>Philippou, A., Halapas, A., Maridaki, M., &amp; Koutsilieris, M. (2007). IGF-1 and exercise: A review of the current evidence of the effects of exercise on IGF-1 levels and actions. <em>Hormones<\/em>, 6(2), 87-95. <a href=\"https:\/\/doi.org\/10.14310\/horm.2002.10804\" rel=\"noopener noreferrer\" target=\"_self\">https:\/\/doi.org\/10.14310\/horm.2002.10804<\/a>. Clemmons, D. R. (2004). IGF-binding proteins: Regulators of IGF actions. <em>Journal of Molecular Endocrinology<\/em>, 32(1), 13-24. <a href=\"https:\/\/doi.org\/10.1677\/jme.1.01578\" rel=\"noopener noreferrer\" target=\"_self\">https:\/\/doi.org\/10.1677\/jme.1.01578<\/a><\/li>\n<li>Musaro, A. (2013). <em>Biochemical Society Transactions<\/em>, 41(6), 1451-1456. <a href=\"https:\/\/doi.org\/10.1042\/BST20130135\" rel=\"noopener noreferrer\" target=\"_self\">https:\/\/doi.org\/10.1042\/BST20130135<\/a><\/li>\n<li>Le Roith, D. (2003). IGFs. <em>The New England Journal of Medicine<\/em>, 336(9), 633-640. <a href=\"https:\/\/doi.org\/10.1056\/NEJM199702273360906\" rel=\"noopener noreferrer\" target=\"_self\">https:\/\/doi.org\/10.1056\/NEJM199702273360906<\/a><\/li>\n<li>Philippou, A., Maridaki, M., &amp; Koutsilieris, M. (2010). <em>Cell Communication and Signaling<\/em>, 8, 15. <a href=\"https:\/\/doi.org\/10.1186\/1478-811X-8-15\" rel=\"noopener noreferrer\" target=\"_self\">https:\/\/doi.org\/10.1186\/1478-811X-8-15<\/a><\/li>\n<li>World Anti-Doping Agency. (2024). Prohibited List. Retrieved from <a href=\"https:\/\/www.wada-ama.org\/en\/prohibited-list\" rel=\"noopener noreferrer\" target=\"_self\">https:\/\/www.wada-ama.org\/en\/prohibited-list<\/a><\/li>\n<li>Lu, H., Huang, D., Saederup, N., Charo, I. F., Ransohoff, R. M., &amp; Zhou, L. (2011). <em>FASEB Journal<\/em>, 25(1), 358-369. <a href=\"https:\/\/doi.org\/10.1096\/fj.10-171579\" rel=\"noopener noreferrer\" target=\"_self\">https:\/\/doi.org\/10.1096\/fj.10-171579<\/a><\/li>\n<li>Scavo, L. M., Karas, M., Murray, M., &amp; Leroith, D. (2004). IGF-I stimulates both cell growth and lipogenesis during differentiation of human mesenchymal stem cells into adipocytes. <em>Journal of Clinical Endocrinology &amp; Metabolism<\/em>, 89(7), 3543-3553. <a href=\"https:\/\/doi.org\/10.1210\/jc.2003-031842\" rel=\"noopener noreferrer\" target=\"_self\">https:\/\/doi.org\/10.1210\/jc.2003-031842<\/a><\/li>\n<\/ol>\n\n","protected":false},"excerpt":{"rendered":"<p> IGF-1 is often compared to other growth factors because of its impact on cellular growth [\u2026]\n","protected":false},"author":1,"featured_media":232,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-231","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=231"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/231\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/232"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}